Okay, let's tackle this question. The user wants me to explain why a certain answer is correct for a question about enzyme replacement therapy. First, I need to remember which disorders are treated with ERT. Common ones include lysosomal storage diseases like Gaucher's disease, Pompe disease, Fabry disease, and maybe Hunter syndrome.

The question is asking for which disorder ERT is available. The correct answer in the example given is Gaucher's disease. So I need to structure the explanation around that. The core concept here is lysosomal storage diseases and their management. I should mention that ERT works by replacing the deficient enzyme.

For the correct answer section, I'll explain that Gaucher's disease is caused by a deficiency in glucocerebrosidase, leading to glucocerebroside accumulation. ERT uses imiglucerase or velaglucerase to break down the substrate.

Now, the wrong options: Let's say the other options are conditions like Diabetes, Alzheimer's, or maybe another metabolic disorder. I need to explain why those aren't treated with ERT. For example, Diabetes uses insulin, not ERT. Alzheimer's has no approved ERT.

Clinical pearls should highlight that ERT is specific to enzyme-deficient disorders. Maybe a mnemonic like "G-P-F-H" for Gaucher, Pompe, Fabry, Hunter.

I need to make sure each section is concise, uses bold for key terms, and stays within the character limit. Let me check the example response to match the structure and ensure all sections are covered properly. Also, avoid markdown except for bold and correct answer line. Alright, that should cover it.

**Core Concept**
Enzyme replacement therapy (ERT) is used to treat lysosomal storage disorders caused by genetic defects in specific enzymes. These disorders involve the accumulation of undigested substrates in lysosomes, leading to organ dysfunction. Key examples include Gaucher’s disease, Pompe disease, and Fabry disease.

**Why the Correct Answer is Right**
Gaucher’s disease is caused by a deficiency of **glucocerebrosidase**, leading to accumulation of glucocerebroside in macrophages. ERT with **imiglucerase** or **velaglucerase alfa** replaces the deficient enzyme, reducing substrate buildup and improving symptoms like hepatosplenomegaly and cytopenias. This therapy is FDA-approved and represents the standard of care for non-neuronopathic forms.

**Why Each Wrong Option is Incorrect**
**Option A:** *Diabetes mellitus* is managed with insulin or oral hypoglycemics, not ERT.
**Option B:** *Alzheimer’s disease* lacks an approved ERT; current treatments target amyloid or tau pathology.
**Option C:** *Cystic fibrosis* uses mucolytics and CFTR modulators, not ERT.

**Clinical Pearl / High-Yield Fact**
ERT is **specific to enzyme-deficient lysosomal disorders** (e.g., Gaucher’s, Pompe, Fabry). Remember the acronym **G-P-F-H** for these diseases. Avoid applying ERT to non-lysosomal conditions like diabetes or neurodegenerative diseases, which are exam traps.

**Correct Answer: C. Gaucher’s disease**

✓ Correct Answer: A. Gaucher disease